Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New
Open Access
- 28 April 2025
- journal article
- review article
- Published by MDPI AG in Hematology Reports
- Vol. 17 (3) , 23
Abstract
Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare and aggressive non-Hodgkin lymphoma (NHL), considered a specific entity with proper characteristics, therapies, and prognosis. First-line treatment is not unique, and subsequent strategies in case of disease persistence or relapse are the subject of debate and studies. In this scenario, [18F]FDG PET/CT plays a pivotal role both in characterizing the mediastinal mass, the main feature of PMLBCL, in staging, in restaging during therapy (interim PET), and at the end of treatment (EoT PET), to guide clinical management and give prognostic insights. The main issue with PMLBCL is distinguishing viable disease from residual fibrotic/inflammatory mass after therapy and, consequently, settling the next clinical strategy. Novel therapeutic approaches are ongoing and associated with the deepening of [18F]FDG PET/CT potentials as a principal tool in this context. In this review, we will explore PMLBCL from a Nuclear Medicine point of view to help clinicians in the management of these patients.Keywords
This publication has 127 references indexed in Scilit:
- Diagnostic accuracy of whole-body magnetic resonance imaging versus positron emission tomography-computed tomography for the staging of pediatric lymphoma: a systematic review and meta-analysisPediatric Radiology, 2023
- Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective studyCancer Medicine, 2021
- Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPThe Oncologist, 2021
- Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphomaCancer Medicine, 2019
- Role of radiation therapy in primary mediastinal large B‐cell lymphoma in rituximab era: A US population‐based analysisAmerican Journal of Hematology, 2015
- The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B‐cell lymphoma: experience on 74 patientsHematological Oncology, 2014
- The role of FDG‐PET imaging as a prognostic marker of outcome in primary mediastinal B‐cell lymphomaCancer Medicine, 2014
- Isolated central nervous system relapses in primary mediastinal large B‐cell lymphoma after CHOP‐like chemotherapy with or without RituximabHematological Oncology, 2012
- Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011